AbCellera Presents Data on T-Cell Engager Platform at SITC 2024
07 Nov 2024 //
BUSINESSWIRE
AbCellera Reports Q3 2024 Business Results
04 Nov 2024 //
BUSINESSWIRE
AbCellera To Present At November 2024 Investor Conferences
22 Oct 2024 //
BUSINESSWIRE
AbCellera Announces T-cell Engager Presentation At SITC Meeting
04 Oct 2024 //
BUSINESSWIRE
AbCellera To Report Q3 2024 Results On November 4
26 Sep 2024 //
BUSINESSWIRE
AbCellera to Present at Upcoming Investor Conferences in September
29 Aug 2024 //
BUSINESSWIRE
AbCellera Reports Q2 2024 Business Results
06 Aug 2024 //
BUSINESSWIRE
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
31 Jul 2024 //
BUSINESSWIRE
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
25 Jun 2024 //
BUSINESSWIRE
AbCellera: To Present At Goldman Sachs Healthcare Conference
28 May 2024 //
BUSINESSWIRE
AbCellera, VCs Launch New Biotech Companies Collaboration
01 May 2024 //
BUSINESSWIRE
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR
08 Apr 2024 //
BUSINESSWIRE
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
03 Apr 2024 //
BUSINESSWIRE
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
19 Mar 2024 //
BUSINESSWIRE
AbCellera to Collaborate with Biogen
11 Mar 2024 //
BUSINESSWIRE
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
05 Mar 2024 //
BUSINESSWIRE
AbCellera Announces Resignation of Board Member
23 Feb 2024 //
BUSINESSWIRE
AbCellera to Present at Upcoming Investor Conferences in March
22 Feb 2024 //
BUSINESSWIRE
AbCellera Reports Full Year 2023 Business Results
20 Feb 2024 //
BUSINESSWIRE
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
23 Jan 2024 //
BUSINESSWIRE
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference
20 Dec 2023 //
BUSINESSWIRE
Vancouver-based antibody therapy firm AbCellera to lay off 10% of workforce
29 Nov 2023 //
CBC
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference
16 Nov 2023 //
BUSINESSWIRE
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
03 Nov 2023 //
BUSINESSWIRE
AbCellera Reports Q3 2023 Business Results
02 Nov 2023 //
BUSINESSWIRE
Prelude Therapeutics and AbCellera Enter Partnership
01 Nov 2023 //
GLOBENEWSWIRE
AbCellera to Present at the Jefferies London Healthcare Conference
31 Oct 2023 //
BUSINESSWIRE
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
11 Oct 2023 //
BUSINESSWIRE
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
27 Sep 2023 //
BUSINESSWIRE
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
20 Sep 2023 //
BUSINESSWIRE
AbCellera Announces Collaboration with Incyte for Antibodies in Oncology
13 Sep 2023 //
BUSINESSWIRE
AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
13 Sep 2023 //
CONTRACT PHARMA
AbCellera Reports Q2 2023 Business Results
03 Aug 2023 //
BUSINESSWIRE
AbCellera hopes to restart patent infringement lawsuits against Berkeley Lights
25 Jul 2023 //
ENDPTS
AbCellera Announces Board Has Denied Berkeley Lights’ Request for Rehearing
24 Jul 2023 //
BUSINESSWIRE
AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023
06 Jul 2023 //
BUSINESSWIRE
AbCellera to Present at the Goldman Sachs 44th Annual Healthcare Conference
29 May 2023 //
BUSINESSWIRE
AbCellera & Canada to invest $500M+ to boost antibody manufacturing and research
25 May 2023 //
ENPTS
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
17 Apr 2023 //
BUSINESSWIRE
AbCellera to Present at Bloom Burton & Co. Healthcare Conference on April 25
11 Apr 2023 //
BUSINESSWIRE
AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
06 Apr 2023 //
BUSINESSWIRE
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies
22 Mar 2023 //
BUSINESSWIRE
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
14 Mar 2023 //
BUSINESSWIRE
AbCellera to Present at Cowen 43rd Annual Health Care Conference on March 6
23 Feb 2023 //
BUSINESSWIRE
AbCellera Reports Full Year 2022 Business Results
22 Feb 2023 //
BUSINESSWIRE
AbCellera Reports Full Year 2022 Business Results
21 Feb 2023 //
BUSINESSWIRE
AbCellera to Present at SVB Biopharma Conference on February 15, 2023
01 Feb 2023 //
BUSINESSWIRE
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
24 Jan 2023 //
BUSINESSWIRE
AbCellera Announces U.S. Patent Trial Upholds Microfluidic Cell Culture Patent
19 Jan 2023 //
BUSINESSWIRE
AbCellera to Present at J.P. Morgan Healthcare Conference on January 11, 2023
04 Jan 2023 //
BUSINESSWIRE
AbCellera and AbbVie Partner to Advance New Antibody Therapies
16 Dec 2022 //
BUSINESSWIRE
Rallybio revs up antibody discovery activities with risk-sharing AbCellera pact
02 Dec 2022 //
FIERCEBIOTECH
AbCellera and Rallybio Announce Strategic Alliance to Discover, Rare Diseases
01 Dec 2022 //
BUSINESSWIRE
Rallybio revs up antibody discovery activities in AbCellera pact
01 Dec 2022 //
FIERCEBIOTECH
Moderna picks up another antibody discovery deal via Harbour BioMed
11 Nov 2022 //
ENDPTS
AbCellera Presents New Data on Further Develop of T-Cell Engagerat SITC 2022
10 Nov 2022 //
BUSINESSWIRE
AbCellera Reports Q3 2022 Business Results
08 Nov 2022 //
BUSINESSWIRE
AbCellera to Present at Upcoming Investor Conferences in November
04 Nov 2022 //
BUSINESSWIRE
AbCellera’s First Program with Regeneron in Multi-Target Collaboration
02 Nov 2022 //
BUSINESSWIRE
AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022
11 Oct 2022 //
BUSINESSWIRE